AGC Biologics Signs TCR-T Cell Services Agreement to Support Medigene’s New Cell Therapy Product | BioSpace

[ad_1] SEATTLE–(BUSINESS WIRE)– AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new service agreement with Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime…